LES Foundation | LESI | Print Page | Contact Us | Sign In | Join
Detailed Schedule
Share |

LES 2015 Spring Meeting

Meeting Home | Schedule | Speakers | Continuing Education | Presentations

Detailed Schedule

Monday, May 11

12:00 PM - 1:00 PM

LES Foundation 2015 Graduate Student Business Plan Competition (off-site)

Tuesday, May 12

9:00 AM

Board of Trustees' Meeting

Pre-Meeting Workshops & Education Courses

(Additional fees are associated with the below pre-meeting workshops and courses)
Register here.

8:00 AM - 5:00 PM

IP Business Basics 101
This new, one-day, deal-centric course has been designed by experienced LES executives for business and licensing (newer to the field) professionals in USA & Canada. Whether it is a trademark, international brand, copyright, patent, knowhow, trade secrets or a combination of some/all of these, recent transactions and auctions have confirmed the value of IP in business. This course is interactive and built around real-world examples and small group hands-on exercises.

Presenter
Ada Nielsen, CEO, Foodexus LLC
Jeffrey Cozzo, Account Executive, IP.com
Matthew C. McNeill, Chief Innovation Officer, VP: IP, Technology & Strategic Alliances, Rite-Hite

12:00

Trustees' Luncheon
IP Business Basics 101 Course Luncheon

2:00 PM - 5:00 PM

Valuation to Support Transactions
This interactive education workshop will help attendees learn how valuation and the valuation process can be used to support negotiations and transactions.Through a combination of case studies, roundtable and group discussions, this facilitated workshop will help licensing executives be better prepared to identify value drivers, analyze potential deal terms, and successfully execute IP-related transactions. Related topics include negotiating financial terms and accounting for risk through deal structure. Attendees will be asked to share their experience, expertise and questions through small team and group discussion.

2:00 PM - 5:00 PM

Getting a Workable License Agreement to Signature --- Practical Tips for Drafting, Legal Review, and Negotiation
This class will be a cross between a review of key licensing basics and a master class of pro tips. It will use an innovative pedagogical technique, pioneered by a Harvard physics professor, in which students work in small groups to brainstorm problem sets based on frequently-occurring negotiation challenges, then compare notes to share best practices. Extensive, easy-to-read written materials will be made available via the Web; students are encouraged to bring notebook computers or tablets for in-class access.

2:00 PM - 5:00 PM CEEM Add-On Workshop
Biofuels, Lessons Learned and Future Avenues

Moderator
Cynthia Cannady, Esq., Founder, IP*SEVA

Panel
"Biofuels, the Science: 1st and 2nd generation biofuels, enzymes, and related technologies"
Speaker: Barry Olafson, Ph.D., CEO, Protabit

"How Algae Could Change the World" 
Speaker: Stephen Mayfield, Ph.D., Director, California Center for Algae Biotechnology, University of California at San Diego

"Biofuels and Patents: "White Space Opportunities and Acquisition Potential"
Speaker: Mary Rose Scozzafava, Ph.D, Esq., Partner, Wilmer Hale

"Biofuels Policy, National Priorities and R&D"
Speaker: Walter Copan, Ph.D., Managing Director, EnergyInsight

Each speaker gives a 10-15 minute presentation.

Moderator will then facilitate discussion on the following questions:

  1. What are the challenges facing research, development and commercialization of biofuels technology?
  2. How can those challenges be overcome?
  3. What opportunities exist for domestic and international collaboration agreements and licensing agreements in biofuels?

ROUNDTABLE
Small group discussions on each of the 4 questions. All groups return to the larger group with their "reports", summarizing their groups’ thoughts. A rapporteur makes notes and summarizes the discussion reports.

6:00 PM - 7:30 PM

Welcome Reception
(This reception is included with the Spring Meeting registration. Those attending the pre-meeting workshops only can add this event for an additional fee.)

Wednesday, May 13

8:00 AM

Committee Meetings

8:45 AM

Opening Remarks
Pamela Demain, LES President, Merck & Co., Inc.

9:00 AM - 10:15 AM

Plenary Session
Innovation vs. Legislation: How Legal Changes Are Affecting Technology Companies


Moderator
Brian O'Shaughnessy, Shareholder, Ratner Prestia

Panelists
Joseph P. Allen, President, Allen and Associates​
David Jones, Assistant General Counsel, Intellectual Property Policy, Microsoft
David Winwood, Incoming Head, AUTM

10:15 AM

Networking Break

10:45 AM - 12:00 PM Concurrent Workshop Sessions #1

10:45 AM - 12:00 PM

Valuation Workshop
Assessing and Incorporating Risk and Uncertainty in the Valuation of Early-Stage Intellectual Property

Valuing early-stage, technology-based intellectual property (IP) assets is challenging, in large part due to the difficulty in incorporating the effects of risk and uncertainty inherent in these assets into their valuation. However, there are various valuation procedures and tools available to appraisers that are helpful in addressing this challenge. This presentation will provide licensing and other professionals interested in valuing early stage technology IP with perspectives that should improve the accuracy and defensibility of their appraisals. Topics that will be covered during this presentation will include: an overview of valuation approaches; relevant risks to consider; the importance of due diligence in identifying and assessing risk and uncertainty; methods for quantifying risk and uncertainty; relevant analytical tools such as the use of scenarios, decision trees, and the Monte Carlo method; and the importance of reasonableness tests.

Panelists
Michael Bredahl, Leader of the International IP Ownership/Royalty Model, Cargill, Inc.
Joseph J. Daniele, PhD, Chief Operating Officer, Acorn Technologies, Inc.
Scott Weingust, Leader of Intellectual Property Valuation Services, Stout Risius Ross, Inc. (SRR)

10:45 AM - 12:00 PM

Life Sciences Workshop
Just Add Water: Creating a Clinical-Stage Company through In-licensing

The flurry of acquisitions and mergers among big pharma has left a dearth of innovative, clinical-stage products on the shelf that don’t quite fit. In addition, academics and biopharma alike often have more programs than their investors are willing to fund. The result is a goldmine for entrepreneurs looking to hit the ground running with an instant pipeline. These panelists will discuss their savvy in-licensing strategies, how to get the backing to do it and challenges along the way. In addition, the panelists will analyze recent in-licensing deals in the news.

Moderator
Douglas MacDougall, President, MacDougall Biomedical Communications

Panelists
Kerrie Brady, Chief Business Officer, Centrexion
Michael Grey, CEO, Reneo Pharmaceuticals
Niall O'Donnell, Ph.D., Managing Director, RiverVest
Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer, Spectrum Pharmaceuticals

10:45 AM - 12:00 PM

High Tech Workshop
Big Data: Current Technologies and Future Opportunities

Big data is an umbrella term used to describe the collection, storage, analysis, protection, and destruction of significant amounts of data, typically for customer and market insights. This presentation will provide an overview of the emerging and incumbent big data technologies and companies, discuss current licensing opportunities created by our present big data environment, and present near-future innovation areas that are likely to lead to market growth and additional licensing prospects.

Panelists
Scott Forbes, Senior Director, Intellectual Ventures
Tamir Koch, CEO, TriPlay Inc.

12:00

Luncheon Featured Speaker
Eric Reifschneider, Senior Vice President and General Manager, Qualcomm Technology Licensing

Luncheon Panel
Niklas Ostman, Senior Director of Licensing, Microsoft
Prathiba M. Singh, Senior Advocate, Delhi High Court

2:00 PM - 3:15 PM Concurrent Workshop Sessions #2

2:00 PM - 3:15 PM

High Tech Workshop
Understanding Commercial Successes in Advanced Science and Technology – The Role of Technology Transfer Offices and Research Institutions

Many developments in advanced sciences and technology (“AST”) originate at universities or research institutions and are facilitated through Technology Transfer Offices (“TTOs”). This session will discuss various models and measures of successful AST licensing, address potential strengths/weaknesses of metrics often cited and explore alternative means by which accomplishments can be quantified. Specifically, the session will cover topics including, but not necessarily limited to, implications of revenue generation versus entrepreneurship (start-ups); measures of return on research funding, staffing, number of patents and exclusive dealings; efficiency comparisons; economic impact studies; and, very generally, establishment of recognized comparability between TTOs.

Moderator
Nels Pearsall, Economist, Director, ERS Group

Panelists
Steven J. Kubisen, Ph.D., VC and Technology Transfer Director, George Washington University
Troy Niehaus, Director of Business Development, Intellectual Ventures
Jill Uhl, Johns Hopkins University Technology Ventures
Brian Wright, Ph.D., Office of Technology Transfer, Auburn University

2:00 PM - 3:15 PM

High Tech/Valuation Workshop
Monetizing Patents: Risks, Challenges, and Strategies for Operating in an Increasingly “Anti-Patent” Environment

The workshop will focus on strategies for monetizing (i.e., licensing and enforcing) patents in the U.S. in 2015. The present environment in the U.S. has made it increasingly more challenging to license a patent and increasingly easier for others to defend against patent enforcement. The workshop will synthesize lessons learned from relevant Supreme Court and Federal Circuit patent decisions, recent state and federal efforts to enact anti-troll legislation, and the increasing use of post-grant proceedings in the USPTO, and explain the impact of these and other recent developments on patent monetization and defensive strategies.

Panelists
Bruce H. Bernstein, Co-Managing Partner, Greenblum & Bernstein, P.L.C.
P. Branko Pejick, Partner, Greenblum & Bernstein, P.L.C.
Afshin Pishevar, Chief Legal Officer and General Counsel, Hyperloop Technologies, Inc.
Jonathan Spangler, Vice President & Chief Patent Counsel, NuVasive, Inc.
Koenraad Wuyts, Chief Intellectual Property Officer, Koninklijke KPN N.V.

2:00 PM - 3:15 PM

Life Sciences Workshop
Innovation: Pharma's Working to Make the Pie Bigger

As large pharmaceutical companies acknowledge that much of the innovation in the life sciences is happening outside the bricks and mortar that these companies have in place, companies are trying to get access to and foster innovation in different ways. The panel will discuss how the different organizations are working to both bring innovative new science into their organizations as well as help build the innovation ecosystem in healthcare.

2:00 PM - 5:00 PM

Train-The-Trainer
Education Course for individuals interested in teaching IP Business Basics

3:15 PM

Networking Break

3:45 PM - 5:00 PM Concurrent Workshop Sessions #3

3:45 PM - 5:00 PM

Valuation Workshop
Determining Litigation Royalty Rates for Standard Essential Patents

With an increase in litigation involving standard essential patents, there is a heightened need to fully understand the issues relating to the determination of Fair Reasonable and Non-Discriminatory (FRAND) royalty rates. In this workshop, we will discuss the considerations reflected in a FRAND royalty rate, and evaluate a number of recent court decisions to identify the specific factors to consider in connection with determining a FRAND royalty rate in litigation. Finally, we will discuss other marketplace developments with the potential to impact the determination of FRAND royalty rates going forward.

Panelist
Michael K. Milani, Managing Director, Ocean Tomo

3:45 PM - 5:00 PM

Life Sciences Workshop
How to Leverage a Platform, Without Taking a Dive
So, you’ve just developed a platform technology, and from this platform, you’d like to launch a thousand, or at least a dozen, new products, through collaborative development. But, your first prospective licensees all want exclusive rights to your technology, to protect themselves given the cost of product development, regulatory trials and commercialization. What to do? We’ll talk to some licensors who have been able to navigate these waters, and come out the other end with multiple partnerships. We’ll also talk to some of the licensees who engaged in this manner, and gauge their satisfaction - all with an eye to creating a better platform licensing strategy.

Moderator
Stacey Nunes, Strategic Partnerships, National Research Council of Canada

Panelists
Michael Attar, Executive Director, Business Development, Celgene
Mark Messenbaugh, Executive Director, Corporate Strategy and Development, SomaLogic Inc.
David Poon, Senior Director, External R&D and Alliances. Zymeworks Inc.
Guy Van Meter, VP, Head of Business Development, Adimab Inc

3:45 PM - 5:00 PM

Licensing in the Direct Response (Infomercial) Industry
Did you ever wonder how a product like the Snuggy or the Total Gym gets to market? Every aspect of the life cycle of these products is governed by one form of license or another. Join us and learn about a little understood, but well-known industry called Direct Response and how the creation of an infomercial to sell a consumer product is all about licensing. From the inventor, to the marketer, to the manufacturer, to the talent appearing in the show, each of these rights is licensed. And finally, discover how you might fit within the DR ecosystem.

Panelist
Al Diem, Director of Business Development, Brand Developers AUS Ltd.

6:30 PM

Off-site Sector Networking Events at Del Mar for High Tech, Life Sciences and IUGI/Other Sectors (additional fees)

THURSDAY MAY 14, 2015

8:00 AM

Committee Meetings

8:45 AM

Welcome Remarks
Mike Fuller, Knobbe Martens
Jim Sobieraj, LESI President

9:00 AM - 10:15 AM

Plenary Session
San Diego Success Stories Roundtable

Moderator
Bruce V. Bigelow, Editor, Xconomy San Diego

Panelists
Alex Dickinson, Illumina
Chrysa Mineo, Receptos
Rory Moore, CEO, EvoNexus

10:15 AM

Networking Break

10:45 AM - 12:00 PM Concurrent Workshop Session #4

10:45 AM - 12:00 PM

High Tech Workshop
The Future of NPE Business Model: Will 2015 Be the Cretaceous for NPE?

As the landscape of IP industry is changing, consolidation of NPE business has started. The dust from Intellectual Ventures’ restructuring has barely settled, and Rockstar is a history now. A once-billion-dollar NPE lost a third of its value in just three months, while Spherix walked away from an acquisition offer by Marathon. Patent brokers have felt the heat, so have patent risk management service providers. NPE lawsuits are trending down, and the recent court rulings indicated that the headwinds faced by NPEs will get stronger and last longer.

So what's next for NPE? Will it become the next dinosaur and 2015 be the Cretaceous? Or will it be a phoenix re-emerging from its ashes? Our panel will bring together a group of industry insiders to address the relevant topics, and beyond, to explore the possible scenarios of the future of NPE business model and its impact on practicing companies, patent lawyers, service providers, and investors.

Moderator
Jack Lu, PhD, CFA, Partner & Chief Economist, IPMAP, LLC

Panelists
Shawn Ambwani, COO, Unified Patents
Kirk Dailey, Head of Patent Transactions, Google
Lawrence Hadley, Principal, McKool Smith

10:45 AM - 12:00 PM

Life Sciences Workshop
Re-emergence of Platform Technologies -- Gonna Party Like It's 1999
.
CAR-T and cell therapy. Stem cells and gene therapy. Massive start-ups and mega-IPOs. It all seems strangely familiar and hauntingly similar to the great genomics era of 1999. Lately clinical events and raised expectations have increasingly hitched investors' biopharma enthusiasm to the CART of platform technology. We know how the last platform era ended -- a massive loss of shareholder value and a decade-long aversion to any investment that was reminiscent of a platform technology. Is there a tunnel at the end of this light -- and how should biotechs prepare to go through it?

Presenter
Mark Edwards, Managing Director, Bioscience Advisors Inc.

12:00

Featured Luncheon Speaker
Standish Fleming, Co-Founder, Forward Ventures

2:00 PM - 3:15 PM Concurrent Workshop Session #5

2:00 PM - 3:15 PM

Life Sciences Workshop
Partnering and Licensing perspectives from the San Diego Not for Profit Research Institutions

This session will feature Life Sciences BD Consultant Linda Pullan, moderating a panel of IP and BD experts from San Diego Independent Research Institutes. Scripps will be represented by Matthew Ritter, Salk by Paul Roben, Sanford-Burnham by Tracie Carroll and La Jolla Institute of Allergy and Immunology by Margaret Hing and Patrick Ho. These four Non-Profit medical research Institutions are known for their collaborations – both with industry and among themselves. Each Institution has recent successful alliances to discuss. However, their status as not-for profit and non-University affiliated creates some unusual challenges as well as some specific advantages to forging partnerships.

Moderator
Linda Pullan, Pullan Consulting

Panelists
Tracie Carroll, Director, Intellectual Property & Licensing, Sanford-Burnham Medical Research Institute
Margaret Hing, Director, Business Development, La Jolla Institute for Allergy and Immunology
Patrick Ho, La Jolla Institute
Matthew Ritter, Scripps
Paul Roben, Salk

2:00 PM - 3:15 PM

High Tech Workshop
Drafting, Incorporating, and Utilizing Arbitration Clauses in License Agreements

When drafting license agreements, attorneys and business people often rely on boilerplate arbitration clauses drafted years, or decades, ago and may not fully understand what they're agreeing to. Negotiating parties retain significant control over the cost and process of litigation when thoughtful arbitration clauses are used. Learn the various aspects of a well-drafted arbitration clause, including considerations for electing arbitration after a dispute has arisen. Hear about the types of disputes that are ideal for arbitration (or mediation) and which might be better left to the courts. Finally, follow the path of a typical arbitration.

Panelists
Kristine Dorrain, Director of Arbitration, Forum
J. Scott Evans, Associate General Counsel, Adobe Systems Incorporated
James H. Grossman, James H. Grossman Arbitration
Sandra Partridge, Managing Director, Forum

3:15 PM

Networking Break

3:45 PM - 5:00 PM Concurrent Workshop Session #6

3:45 PM - 5:00 PM

Patent Litigation: Global Trends and Strategies
With the rise of global economies and international competition, patent litigation has grown into a global phenomenon. Today, patent disputes often extend beyond national borders, with parallel litigations often taking place in multiple forums. The panelists will discuss the most important metrics and techniques to employ in formulating effective global litigation strategies. The strategies are designed to achieve the best, overall business result from the perspective of both the patentee and the alleged infringer. In-house and outside patent litigation counsel will discuss topics relevant to not only their respective countries, but also other major countries.

Moderator
Michael Elmer, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Panelists
Michael Crichton, Gowling Lafleur Henderson LLP
Gregory Gramenopoulos, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Soonhee Jang, Vice President and Chief IP Counsel, Stratasys Ltd.
Keith Newburry, Edwards Lifesciences

3:45 PM - 5:00 PM

Life Sciences Workshop
Life Sciences Global Royalty Rate and Deal Terms Survey

Beyond “BIO $$ Bucks”!

Your Benchmarks are __??....Your analysis is based on __??.... Does NPV matter outside the U.S. …??

Deal Terms: Do You Really Know What's Happening in Your Therapeutic or Geographic Markets?
Many sources of information on biopharmaceutical royalty rates and deal terms rely on the Freedom of Information (FOI) sources available from the U.S. Securities and Exchange Commission or from press releases or public announcements which are often positioned for maximum publicity or promotional impact (i.e. the hyperbole of "BIO Bucks").
What are the strengths and weaknesses of this data? How does it reflect what is happening in “global” deal making?

The Life Sciences Sectors of LES USA/Canada and the Licensing Executive Society International (LESI) partnered to conduct a landmark GLOBAL survey of royalty rates and deal terms. The results represent deals submitted by over 200 companies with approximately one-half the deals submitted by companies outside the USA and Canada.

This landmark global survey is unique in the Life Sciences and Biopharmaceutical industries. The findings provide insights certain to raise questions or challenge conventional thinking, especially for early stage technologies and international deals in the current turbulent years.

The results presented in this session will be highlights of the Global Survey Report published in early 2015. The findings provide insights certain to raise questions or challenge conventional thinking, especially for contemporary deals in recent and turbulent years.

Don’t miss the insights to be learned or the assumptions behind your deal data or that used by your competitors.

Panelists
James A. McCarthy, CLP, Corporate & Commercial Development, Licensing and Alliance Management, CorpDev Ventures
Matt Raymond, President, Kaenn Technologies

5:00 PM

Closing Reception